138 related articles for article (PubMed ID: 24354684)
41. Clinical effects of autologous stem cell transplantation as consolidation treatment in 70 multiple myeloma patients: a case-controlled study.
Zhou LL; Yuan ZG; Fu WJ; Xi H; Zhang CY; Lan HF; Zhang X; Chen Y; Liu WY; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2975-80. PubMed ID: 22040538
[TBL] [Abstract][Full Text] [Related]
42. Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Chim CS; Liu H; Lie AK; Chan EY; Ho S; Wong M; Kwong YL
Hematol Oncol; 2014 Dec; 32(4):205-11. PubMed ID: 24473998
[TBL] [Abstract][Full Text] [Related]
43. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
44. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
[TBL] [Abstract][Full Text] [Related]
45. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
46. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
[TBL] [Abstract][Full Text] [Related]
47. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
48. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
[TBL] [Abstract][Full Text] [Related]
49. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
50. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
51. Predictive impact of circulating microRNA-193a-5p on early relapse after autologous stem cell transplantation in patients with multiple myeloma.
Park SS; Lim JY; Kim TW; Ko YH; Jeon WJ; Lee SY; Lee JH; Min CK
Br J Haematol; 2020 May; 189(3):518-523. PubMed ID: 32030736
[TBL] [Abstract][Full Text] [Related]
52. Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.
Schmitz MF; Otten HG; Franssen LE; van Dorp S; Strooisma T; Lokhorst HM; van de Donk NW
Haematologica; 2014 Dec; 99(12):1846-53. PubMed ID: 25193963
[TBL] [Abstract][Full Text] [Related]
53. Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis.
Rodríguez-Lobato LG; Fernández de Larrea C; Cibeira MT; Tovar N; Aróstegui JI; Rosiñol L; Díaz T; Lozano E; Elena M; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1269-1275. PubMed ID: 28434927
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
[TBL] [Abstract][Full Text] [Related]
55. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
56. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
57. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.
Dingli D; Nowakowski GS; Dispenzieri A; Lacy MQ; Hayman SR; Rajkumar SV; Greipp PR; Litzow MR; Gastineau DA; Witzig TE; Gertz MA
Blood; 2006 Apr; 107(8):3384-8. PubMed ID: 16339399
[TBL] [Abstract][Full Text] [Related]
58. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
van de Velde H; Londhe A; Ataman O; Johns HL; Hill S; Landers E; Berlin JA
Eur J Haematol; 2017 Mar; 98(3):269-279. PubMed ID: 27859769
[TBL] [Abstract][Full Text] [Related]
59. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
[TBL] [Abstract][Full Text] [Related]
60. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
